WEIGHT LOSS WITH MEDICATION
Medical weight loss
Weight loss medications help you regulate your appetite, making it easier to lose weight. The medicine mimics the effect of the body’s natural intestinal hormone, Glucagon, which helps suppress your appetite.
You feel full faster and therefore consume fewer calories.
Weight loss medications lower your appetite
The new method that SLIM for LIFE offers is a medical aid for weight loss with so-called GLP-1/ GLP-1 RA (Glucagon-Like Peptide-1 receptor Agonists), which are produced by Novo Nordisk.
The most effective medicine
Novo Nordisk produces several types of GLP-1 RA products in different formulations, of which the most effective at the moment are  Wegovy ® or  Ozempic ® . Ozempic has been registered in the EU and North America since 2017 and is intended for patients with diabetes (type 2 diabetes), but can also be used for the medical treatment of obesity. Both preparations contain the active substance Semaglutide, but in Wegovy it is in a higher dose.
Semaglutide is injected with a very thin, short needle just under the skin once a week. It is also possible to get Semaglutide in pill form, Rybelsus ®, but the effect is more fluctuating with pills that must be taken daily.
SLIM for LIFE does not prescribe Ozempic® as it is only intended for diabetic patients
What can these experiences mean to you?
In another trial, all were given Wegovy® combined with low-calorie meals and increased physical activity for 20 weeks. These people did not have type 2 diabetes and either had a body mass index (BMI) of 30 or higher or of 27 to 30 with at least 1 weight-related complication.
What can I expect to lose with FIT for LIFE?
There is scientific evidence that patients who use medical treatment for weight loss experience significantly greater weight loss with medication than without (see chart). Both groups are advised on diet and exercise. The gray curve is those who received “cheat medicine” (called placebo), and the blue curve is those who received the active medicine.
The figures are based on an average, with some having significant weight loss (up to 20%), while others have slightly less. So keep an eye on the medicine working so that you can see and feel a weight loss.
If you add lifestyle changes on top, there is an opportunity to turn a large weight loss into a lasting weight loss.
Increased quality of life and reduced risk of disease
Just a few kilos lost in severely obese people has health benefits. A weight loss of 5% or more reduces the risk of type-2 diabetes, improves obstructive sleep apnea and lowers blood pressure.
Greater well-being, more movement and energy, better sleep and greater self-esteem in social contexts are other good reasons to lose weight. We are happy to hold your hand all the way once you have signed up for membership.
Medication approved for weight loss
Wegovy contains the same molecule as Ozempic®, Semaglutide, but the dose of up to 2.4 mg/week is primarily aimed at obesity. Wegovy® is registered for the treatment of mildly obese (BMI over 27-30), if there are other risk factors at the same time, and for more severe obesity with BMI +30 in the USA. It is approved by the European Medicines Agency (EMA) and thus also approved for use in Denmark.
This is how the medicine works
The medicine works by stimulating the release of insulin and inhibiting the release of glucagon. Glucagon is a hormone that, like insulin, is produced in the pancreas, but has the opposite effect.
The agent also delays the absorption of glucose from the intestine. This reduces the sugar content in the blood. Blood fat/cholesterol in the blood will therefore also fall in a favorable direction.
Prevents sequelae
Weight loss medication can effectively prevent the development of obesity-related sequelae such as cancer, cardiovascular disease, high blood pressure, diabetes, fatty liver, reduced sexual function, reduced fertility, reduced male sex hormones in men, pain/osteoarthritis in the back, hips and knees and early death.
In addition to providing a large weight loss, the medicine reduces the risk of the at least 60 secondary diseases associated with obesity.
